Life Science Company News

Ossur Hf :Transactions in relation to share buyback program

Announcement from Össur hf. No. 5/2018
Reykjavík, 22 January 2018

On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. 

The purpose of the share buyback program is to reduce the Company's share capital and adjust the capital structure by distributing capital to shareholders in line with the Company's Capital Structure and Dividend Policy. The program will end no later than 31 July 2018. The Company may purchase up to 5,000,000 shares under the program, corresponding to 1.1% of the current share capital. The total consideration for shares purchased under the program shall not exceed USD 10 million.

The following transactions were made under the program in week 23, the period 15 January 2018 - 19 January 2018:

Date No. of shares Avg. purchase price DKK Transaction Value DKK
15 January 2018 111,715 30.28 3,383,199
16 January 2018 5,000 29.90 149,500
17 January 2018 2,753 29.55 81,364
18 January 2018 3,161 29.52 93,310
19 January 2018 7,100 29.92 212,466
Total   129,729 29.57 3,919,839
       

Össur has acquired 1,348,698 shares under the program at the average price of DKK 29.27. Following the above transactions Össur's holding of own shares is 9,465,303 corresponding to 2.17% of the Company's total share capital.

The share buyback program is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission delegated regulation No. 2016/1052.                                                                                                                           

                                                                                                                     

Contact persons:

Jón Sigurðsson, President & CEO                                       Tel: +354 515 1300
Sveinn Sölvason, CFO                                                       Tel: +354 515 1300

Össur press releases by e-mail: If you wish to receive Össur press releases by e-mail please register at the following web-site: http://www.ossur.com/investormailings

About Össur Össur (NASDAQ: OSSR) is a global leader in non-invasive orthopedics that help people live a life without limitations. Its business is focused on improving people's mobility through the delivery of innovative technologies within the fields of braces, supports and prosthetic limbs. A recognized "Technology Pioneer", Össur invests significantly in research and product development; its award-winning designs ensuring a consistently strong position in the market. Successful patient and clinical outcomes are further empowered via Össur's educational programs and business solutions.  Headquartered in Iceland, Össur has major operations in the Americas, Europe and Asia, with additional distributors worldwide. www.ossur.com

Forward-Looking Statement This press release includes "forward-looking statements" which involve risks and uncertainties that could cause actual results to differ materially from results expressed or implied by these statements. Össur hf. undertakes no obligation and does not intend to update these forward-looking statements to reflect events or circumstances occurring after this press release. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement.

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/91ba0889-d5ab-4424-9499-b50e67dfda30

By: Nasdaq / GlobeNewswire - 22 Jan 2018
Back to overview

Enhance your business development with Biotechgate